Researchers Submit Patent Application, "Compound For Treating Non-Alcoholic Fatty Liver Disease And Related Diseases", for Approval (USPTO 20240423946).

A patent application has been submitted for a compound aimed at treating non-alcoholic fatty liver disease (NAFLD) and related conditions. NAFLD affects a significant portion of the global population, with a high prevalence in developed nations like the United States. The compound targets hepatic steatosis and inflammation associated with NAFLD, offering potential therapeutic benefits for patients. The lack of FDA-approved therapies for NAFLD underscores the urgent need for effective treatments to address this growing health concern. [Extracted from the article]